Lomefloxacin pharmacokinetics were investigated in 6 normal subjects and 24 uremic patients after a single oral dose of 400 mg. In subjects with normal renal function, the peak level in plasma averaged 3.5 0.9 ,g/ml (mean + standard deviation) and was obtained at 1.3 0.9 h. The absorption rate constant was 3.8 1.6 h-'.
Lomefloxacin (SC-47111; NY-198) is a new difluorinated quinolone derivative characterized by a broad antibacterial spectrum. It has been shown to have activity against both gram-negative and gram-positive bacteria, including bacteria resistant to beta-lactam antibiotics and aminoglycosides (5, 9) . The activity of lomefloxacin was roughly comparable to the activities of ofloxacin and norfloxacin but far exceeded that of pipemidic acid (5) . The purpose of this study was to determine the pharmacokinetic parameters of lomefloxacin in subjects with normal and impaired renal function after a single oral dose of 400 mg.
(A part of this study was presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy in Los Angeles, Calif. [A. Leroy, G. Humbert, F. Borsa, and J. P. Fillastre, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 54, 1988] .) MATERLALS AND METHODS Subjects. Thirty subjects with no known susceptibility to quinolone derivatives participated in the study after ethical committee approval and written informed consent had been obtained. The characteristics of the subjects are given in Table 1 .
Six adult male volunteers, aged from 24 to 33 years and weighing from 67 to 82 kg, were selected for the study. These subjects had no evidence of hepatic, hematological, or renal disease confirmed by physical examination and biological tests. Their renal function was normal, with a mean endogenous creatinine clearance (CLCR) of 135 ml/min. Twenty-four subjects had chronic renal impairment with stable CLCRs during the previous 6 months. The subjects were divided into four groups on the basis of glomerular filtration rate (GFR), as determined by CLCR: group 1 (mild renal impairment; n = 6), 32 to 65 mlmin; group 2 (moderate renal impairment; n = 6), 12 to 28 ml/min; group 3 (severe * Corresponding author. renal impairment; n = 6), 4 to 9 ml/min; and group 4 (hemodialysis patients; n = 6).
It is to be noted that the normal volunteers were younger than all the uremic patients and had high CLCRs.
Patients taking barbiturates, phenytoin, rifampin, antacids, and calcium salts were excluded from the study.
Study design. All subjects fasted overnight before the study and for 2 h after lomefloxacin administration. They were given a single oral dose of 400 mg of lomefloxacin. Two hours after dosing, all subjects had breakfast; thereafter, food and drink were available ad libitum.
Sampling. Blood Hemodialysis was performed with a Cuprophanne membrane (1.2 M2; Travenol CF 1511) with a constant blood flow rate of 300 ml/min and dialysate flow rates of 500 ml/min for four patients and 1,000 ml/min for the two other patients.
Plasma and urine samples were stored frozen at -80°C until assay.
Assay technique. Concentrations of lomefloxacin in plasma and urine were measured by microbiological assay with Escherichia coli 1346 as the test strain. The medium used was antibiotic medium number 1 (Difco Laboratories) (pH 6.6). Standards were prepared with pooled human serum for plasma samples and with phosphate buffer (pH 7) for urine samples. No significant difference was observed in the antimicrobial activities of lomefloxacin measured in plasma or serum samples, so a pooled human serum without antibiotic could be used as the diluent of the plasma samples. The plates were incubated overnight at 37°C. The linear regression analysis of the standard calibration lines obtained by plotting the log antibiotic concentrations versus the zone diameters of inhibition indicated excellent linearity of the assay between 0.16 and 5.00 ,ug/ml. The sensitivity limit of the assay was 0.05 ,ug/ml. The coefficients of variation of the assay were 8% at 5 ,ug/ml and 10% at 0.16 jig/ml. CLCR was measured. Blood and urine creatinine concentrations were assayed by the method of Jaffe.
Pharmacokinetic analysis. The pharmacokinetic analysis was performed by analysis of individual data and routine graphical methods (4) .
The individual concentrations of lomefloxacin in plasma versus time were best described by a biexponential equation chosen on the basis of visual inspection and the F ratio test (1) . The peak concentration in plasma (Cmax) and the time to peak (Tmax) reported were the experimental values. The apparent terminal elimination rate constant (kel) was calculated by least-squares regression analysis on the terminal portion of the plasma concentration-time profile. The elimination half-life (tQ12) was calculated from k,, (t112 = ln 2/ke,).
The absorption phase was estimated by using the unweighted method of residuals, and the apparent absorption Fig. 1 ). After the same dose as in normal subjects, the lomefloxacin Cmax and Tm. were not significantly modified in uremic patients (P = 0.44 and P = 0.84, respectively).
Renal impairment did not significantly modify the V/F in normal subjects and group 3 patients (P = 0.10). The kas were not statistically different in normal subjects and uremic patients (P = 0.98).
The CL/F and CLR of lomefloxacin decreased in relation to the degree of renal failure. The nonrenal clearance (CLNR) of lomefloxacin (CL/F -CLR) was statistically unchanged in subjects with normal and impaired renal function. CLNRs were 59.4 ± 33.1 mllmin per 1.73 m2 in normal subjects and 38.3 ± 15.8, 43.7 ± 4.9, and 51.2 ± 13.2 ml/min per 1.73 m2 in group 1, 2, and 3 patients, respectively (P = 0.39). Urinary excretion of lomefloxacin decreased and was delayed in patients with renal failure.
Hemodialysis patients (group 4). For group 4 patients, the pharmacokinetic data of lomefloxacin were calculated both off and on hemodialysis.
During the first 48 h before hemodialysis, the following kinetic parameters were obtained: Cmax, 4 DISCUSSION Normal subjects. In normal subjects, the pharmacokinetic parameters of lomefloxacin found in our study are in good agreement with those reported by others (6, 8) . In a previous study performed by Morrison et al. (6) with healthy subjects receiving five doses of lomefloxacin (100, 200, 400, 600, and 800 mg), lomefloxacin pharmacokinetics were found to be dose independent. The high urinary recovery of unchanged lomefloxacin suggests that nonrenal mechanisms account for no more than 15 to 25% of its elimination.
Uremic patients. The lomefloxacin t1/2 increased in relation to the degree of renal failure, reaching values fivefold higher than those obtained in normal subjects, in patients with end-stage renal dysfunction in 38 and 8 h. However, the Cma and Tmax remained unchanged whatever the degree of renal impairment. Linear relationships were established between lomefloxacin pharmacokinetic parameters and GFR data ( Fig. 2 and 3) .
From the relation between CL/F and CLR (Fig. 2) , the CLNR of lomefloxacin could be evaluated as 41 ml/min per 1.73 M2; i.e., about 15% of the CL/F in normal subjects. The present study showed that the concentrations of lomefloxacin measured in plasma after a single 400-mg dose remained above the MIC for most susceptible bacteria, i.e., -1 ,ug/ml, for 8 to 10 h in normal subjects and for 32 to 48 h in group 1, 2, and 3 patients. High concentrations of lomefloxacin found in 24-h urine in both normal subjects and uremic patients suggest that once-daily dosing should be sufficient to treat urinary infections caused by susceptible organisms.
In the treatment of systemic infections, dosage adjustments of lomefloxacin are necessary in relation to the degree (Table 3 ).
In conclusion, lomefloxacin pharmacokinetics are characterized by a rapid absorption, a long t1/2 (-8 h), and a large V/F. Lomefloxacin is almost exclusively excreted unchanged in urine (80 to 85%); thus, metabolism appears to occur to a lesser extent (<20%).
The important increase in t112 of lomefloxacin observed in patients with chronic renal impairment requires dosage adjustments of lomefloxacin in relation to the degree of renal failure.
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